Access through your institution

通过您的机构访问

Buy or subscribe

购买或订阅

Patients with advanced-stage neuroendocrine tumours (NETs) have limited treatment options following disease progression after 1–2 lines of systemic therapy. Now, newly published data from the phase III CABINET trial, simultaneously presented at the ESMO Congress 2024, demonstrate the efficacy of cabozantinib in this setting.In CABINET, patients with locally advanced or metastatic well or moderately differentiated extrapancreatic (n = 203) or pancreatic (n = 95) NETs previously treated with at least one FDA-approved systemic therapy were randomly assigned, 2:1, to either cabozantinib or placebo.

晚期神经内分泌肿瘤（NETs）患者在1-2行全身治疗后疾病进展后，治疗选择有限。现在，同时在2024年ESMO大会上公布的第三阶段内阁试验的最新数据证明了卡博替尼在这种情况下的疗效。在内阁中，先前接受至少一种FDA批准的全身治疗的局部晚期或转移性胰腺外分化良好或中度分化（n=203）或胰腺（n=95）NETs患者被随机分配到卡博替尼或安慰剂组，比例为2:1。

Most patients had received 177Lu-dotatate (~59%) and/or everolimus (~72%), and ~26% of those with pancreatic NETs had received sunitinib. Progression-free survival (PFS) was the primary end point..

大多数患者接受了177Lu-dotatate（〜59%）和/或依维莫司（〜72%），胰腺NETs患者中约26%接受了舒尼替尼治疗。无进展生存期（PFS）是主要终点。。

This is a preview of subscription content, access via your institution

这是订阅内容的预览，可通过您的机构访问

Access options

访问选项

Access through your institution

通过您的机构访问

Access through your institution

通过您的机构访问

Change institution

变革机构

Buy or subscribe

购买或订阅

Access Nature and 54 other Nature Portfolio journalsGet Nature+, our best-value online-access subscription24,99 € / 30 dayscancel any timeLearn moreSubscription info for Chinese customersWe have a dedicated website for our Chinese customers. Please go to naturechina.com to subscribe to this journal.Go to naturechina.comBuy this articlePurchase on SpringerLinkInstant access to full article PDFBuy nowPrices may be subject to local taxes which are calculated during checkout.

Access Nature和54篇其他Nature Portfolio journalsGet Nature+，我们最有价值的在线订阅24,99欧元/30天，随时为中国客户获取更多订阅信息我们为中国客户提供了一个专门的网站。请访问naturechina.com订阅本期刊。访问naturechina.comBuy本文在Springerlink上购买即时访问完整文章PDFBuy Now价格可能需要缴纳结帐时计算的地方税。

Additional access options:

其他访问选项：

Log in

登录

Learn about institutional subscriptions

了解机构订阅

Read our FAQs

阅读我们的常见问题

Contact customer support

联系客户支持

ReferencesOriginal articleChan, J. A. et al. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2403991 (2024)Article

参考文献cabozantinib治疗晚期神经内分泌肿瘤的3期临床试验。N、 。J、 医学。https://doi.org/10.1056/NEJMoa2403991（2024）条

PubMed

PubMed

PubMed Central

公共医学中心

Google Scholar

谷歌学者

Download referencesAuthor informationAuthors and AffiliationsNature Reviews Clinical Oncology http://www.nature.com/nrclinoncDavid KillockAuthorsDavid KillockView author publicationsYou can also search for this author in

下载参考文献作者信息作者和附属机构临床肿瘤学评论http://www.nature.com/nrclinoncDavidKillockAuthorsDavidKillockView作者出版物您也可以在

PubMed Google ScholarCorresponding authorCorrespondence to

PubMed谷歌学者通讯社

David Killock.Rights and permissionsReprints and permissionsAbout this articleCite this articleKillock, D. CABINET presents cabozantinib as a new treatment option for NETs.

大卫·基洛克。权利和许可打印和许可本文引用本文Killock，D.CABINET介绍了cabozantinib作为NETs的新治疗选择。

Nat Rev Clin Oncol (2024). https://doi.org/10.1038/s41571-024-00949-0Download citationPublished: 24 September 2024DOI: https://doi.org/10.1038/s41571-024-00949-0Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard.

Nat Rev Clin Oncol（2024）。https://doi.org/10.1038/s41571-024-00949-0Download引文发布日期：2024年9月24日OI：https://doi.org/10.1038/s41571-024-00949-0Share本文与您共享以下链接的任何人都可以阅读此内容：获取可共享链接对不起，本文目前没有可共享的链接。复制到剪贴板。

Provided by the Springer Nature SharedIt content-sharing initiative

由Springer Nature SharedIt内容共享计划提供